AARDEX Group is dedicated to advancing clinical research and improving patient outcomes through our innovative solutions for measuring and managing medication adherence. We recognize that clinical trials are complex endeavors requiring multiple stakeholders' involvement, each with unique expertise and capabilities. That's why we have built an ecosystem of partners who share our vision and commitment to improving patient outcomes through clinical trial success.
Our ecosystem includes some of the most prominent and respected names in the industry, including CMOs, CROs, EDC, IRT, DCT vendors, and several industry-leading adherence packaging and device developers. By collaborating with these partners, AARDEX Group is leading the way in streamlining the approach to measuring and managing adherence in various clinical trial settings, including site-based, hybrid, and decentralized.
Our partners bring a wealth of knowledge and expertise to the table. By working together, we can develop innovative solutions that address the unique challenges of clinical trial adherence management. Our collective efforts are transforming how medication adherence is measured and managed, resulting in more accurate data and improved patient outcomes.
At AARDEX Group, we are proud to be part of a network of partners that is making a significant impact on the field of clinical research. Our commitment to advancing clinical trial success through collaboration and innovation is unwavering, and we look forward to continuing to work with our partners to improve the lives of patients everywhere.
Our partners collaborate with us to deliver innovative adherence packaging and devices.
Our partners in Interactive Response Technology (IRT) and Randomization & Trial Supply Management (RTSM) ensure efficient randomization and trial supply management.
Our partnership with Contract Manufacturing Organizations (CMOs) is dedicated to delivering high-quality products.
Our partners bring innovative solutions to make clinical trials more accessible and efficient.
Collaborating with Electronic Data Capture (EDC) providers to improve the reliability and speed of clinical trials, ensuring real-time and accurate data collection.
WEBINAR WITH MERCK & BIOGEN
Mitigating the Risk of Poor Adherence in Trials
Watch this live recording with adherence experts from Merck & Biogen to learn about their approach to mitigating the risk of poor adherence in trials.
FROM THE AARDEX GROUP BLOG
We are thrilled to feature expert insights from Bernard Vrijens, a world-renowned expert on medication adherence. Taking medication as prescribed is crucial to achieving optimal health outcomes, yet non-adherence is a prevalent issue. Bernard Vrijens' extensive research and experience in the field provide invaluable insights into the factors that contribute to medication non-adherence and effective strategies to address them. His contributions to our medication adherence blog offer actionable advice and evidence-based recommendations to improve medication adherence and ultimately, patient outcomes.
They might not always be easily identifiable, but millions of people across the globe are living with the debilitating symptoms of depression. This common mental disorder is thought to affect around 5% of the world’s adult population, with the pandemic
WHO cares. It’s now time you did Why Change is Needed in Clinical Trials? The old adage tells us not to fix things that aren’t broken. Logic suggests, therefore, that whenever a fix is being applied, things aren’t working as
Enhancing Adherence in Clinical Trials: A Strategic Imperative When a high-profile authority in the medical world, such as the World Health Organization (WHO), publishes guidelines on best practices in clinical trials, the industry takes note. Aiming for Reform and Improvement
Nostalgia can trick us into thinking that things were better in the “good old days”. But the world of science is rarely a place where sentimentality should cloud better judgement. Rather, it is a place where questions, analysis and evidence
When bringing a new drug product to market, powerful motivating forces are involved. And while the potential for enhancing, or even extending, the lives of patients unquestionably takes primacy, there is another inescapably influential factor in the mix: profitability. For
The economic model that has underpinned the development of drug products for decades is currently under siege. Faced on one side with mounting pressure from payers to address affordability issues, pharmaceutical companies are facing ever more stringent regulatory requirements alongside